Cynthia Forlini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9004950/publications.pdf

Version: 2024-02-01

50 papers	1,188 citations	394286 19 h-index	395590 33 g-index
53 all docs	53 docs citations	53 times ranked	1142 citing authors

#	Article	IF	Citations
1	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. Lancet Psychiatry,the, 2015, 2, 105-110.	3.7	158
2	Autonomy and Coercion in Academic â€œCognitive Enhancementâ€•Using Methylphenidate: Perspectives of Key Stakeholders. Neuroethics, 2009, 2, 163-177.	1.7	110
3	Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs?. Neuroethics, 2010, 3, 1-4.	1.7	94
4	Food Addiction and Its Impact on Weight-Based Stigma and the Treatment of Obese Individuals in the U.S. and Australia. Nutrients, 2014, 6, 5312-5326.	1.7	68
5	Disagreements with implications: diverging discourses on the ethics of non-medical use of methylphenidate for performance enhancement. BMC Medical Ethics, 2009, 10, 9.	1.0	67
6	Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE, 2013, 8, e71452.	1.1	50
7	Australian University Studentsâ€™ Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers. Frontiers in Psychology, 2016, 7, 277.	1.1	44
8	Stakeholder perspectives and reactions to â€œacademicâ€•cognitive enhancement: Unsuspected meaning of ambivalence and analogies. Public Understanding of Science, 2012, 21, 606-625.	1.6	42
9	Should physicians prescribe cognitive enhancers to healthy individuals?. Cmaj, 2013, 185, 1047-1050.	0.9	41
10	Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction, 2015, 110, 1061-1067.	1.7	40
11	The value and pitfalls of speculation about science and technology in bioethics: the case of cognitive enhancement. Medicine, Health Care and Philosophy, 2014, 17, 325-337.	0.9	38
12	Added Stakeholders, Added Value(s) to the Cognitive Enhancement Debate: Are Academic Discourse and Professional Policies Sidestepping Values of Stakeholders?. American Journal of Bioethics Primary Research, 2012, 3, 33-47.	1.5	32
13	Knowledge, Experiences and Views of German University Students Toward Neuroenhancement: An Empirical-Ethical Analysis. Neuroethics, 2015, 8, 83-92.	1.7	32
14	Researchersâ€™ perspectives on scientific and ethical issues with transcranial direct current stimulation: An international survey. Scientific Reports, 2015, 5, 10618.	1.6	31
15	Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 2009, 35, 469-470.	1.0	28
16	Seeking legitimacy for broad understandings of substance use. International Journal of Drug Policy, 2019, 73, 58-63.	1.6	28
17	Navigating the enhancement landscape. EMBO Reports, 2013, 14, 123-128.	2.0	25
18	Brain disease model of addiction: misplaced priorities?. Lancet Psychiatry,the, 2015, 2, 867.	3.7	22

#	Article	IF	Citations
19	Non-medical prescription stimulant use to improve academic performance among Australian university students: prevalence and correlates of use. BMC Public Health, 2018, 18, 1270.	1.2	21
20	The pharmaceuticalisation of â€˜healthyâ€™ ageing: Testosterone enhancement for longevity. International Journal of Drug Policy, 2021, 95, 103159.	1.6	20
21	Generating genius: how an Alzheimerâ€™s drug became considered a â€˜cognitive enhancerâ€™ for healthy individuals. BMC Medical Ethics, 2014, 15, 37.	1.0	17
22	The is and ought of the Ethics of Neuroenhancement: Mind the Gap. Frontiers in Psychology, 2016, 6, 1998.	1.1	15
23	Problematic risk-taking involving emerging technologies: A stakeholder framework to minimize harms. Journal of Behavioral Addictions, 2021, 9, 869-875.	1.9	15
24	A scoping review of the perceptions of death in the context of organ donation and transplantation. BMC Medical Ethics, 2021, 22, 167.	1.0	13
25	RESPONDING TO REQUESTS FROM ADULT PATIENTS FOR NEUROENHANCEMENTS: GUIDANCE OF THE ETHICS, LAW AND HUMANITIES COMMITTEE. Neurology, 2010, 74, 1555-1556.	1.5	12
26	Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimerâ€™s Disease. Kennedy Institute of Ethics Journal, 2017, 27, 1-41.	0.3	12
27	The Hidden Ethics Curriculum in Two Canadian Psychiatry Residency Programs: A Qualitative Study. Academic Psychiatry, 2016, 40, 592-599.	0.4	11
28	A Neuroethics Framework for the Australian Brain Initiative. Neuron, 2019, 101, 365-369.	3.8	11
29	An Australian community jury to consider caseâ€finding for dementia: Differences between informed community preferences and general practice guidelines. Health Expectations, 2019, 22, 475-484.	1.1	10
30	Considering the Causes and Implications of Ambivalence in Using Medicine for Enhancement. American Journal of Bioethics, 2011, 11, 15-17.	0.5	9
31	How Research on Stakeholder Perspectives Can Inform Policy on Cognitive Enhancement. American Journal of Bioethics, 2013, 13, 41-43.	0.5	8
32	Death, dying and donation: community perceptions of brain death and their relationship to decisions regarding withdrawal of vital organ support and organ donation. Internal Medicine Journal, 2020, 50, 1192-1201.	0.5	7
33	The brain disease model of addiction: challenging or reinforcing stigma?â€“Authors' reply. Lancet Psychiatry,the, 2015, 2, 292.	3.7	6
34	Complementary and Alternative Medicine in the Context of Earlier Diagnoses of Alzheimerâ€™s Disease: Opening the Conversation to Prepare Ethical Responses. Journal of Alzheimer's Disease, 2016, 51, 1-9.	1.2	6
35	Surveillance Medicine in the DigitalEra: Lessons From Addiction Treatment. American Journal of Bioethics, 2018, 18, 58-60.	0.5	5
36	Does the Cognitive Enhancement Debate Call for a Renewal of the Deliberative Role of Bioethics?. Trends in Augmentation of Human Performance, 2013, , 173-186.	0.4	5

#	Article	IF	Citations
37	Popular Media and Bioethics Scholarship: Sharing Responsibility for Portrayals of Cognitive Enhancement with Prescription Medications. , 2015, , 1473-1486.		5
38	A prospectus for ethical analysis of ageing individuals' responsibility to prevent cognitive decline. Bioethics, 2017, 31, 657-665.	0.7	4
39	Public Mental Health Ethics: Helping Improve Mental Health for Individuals and Communities. Public Health Ethics, 2018, 11, 121-125.	0.4	4
40	Empirical Data Is Failing to Break the Ethics Stalemate in the Cognitive Enhancement Debate. AJOB Neuroscience, 2020, 11, 240-242.	0.6	4
41	Beyond Flourishing: Intersecting Uses and Interests in the Neurotechnology Marketplace. AJOB Neuroscience, 2019, 10, 178-180.	0.6	3
42	Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues. , 2015, , 1085-1100.		3
43	Alienation and Authenticity in Parkinson's Disease and Its Treatment. AJOB Neuroscience, 2014, 5, 54-56.	0.6	2
44	Nuances in the ethical regulation of electronic nicotine delivery systems. Addiction, 2015, 110, 1074-1075.	1.7	2
45	Throwing the Ethics (Hand)Book at Professional Organizations in the Neurological Sciences. AJOB Neuroscience, 2017, 8, W1-W2.	0.6	1
46	Death determination, organ donation and the importance of the Dead Donor Rule following withdrawal of lifeâ€sustaining treatment: A survey of community opinions. Internal Medicine Journal, 2021, , .	0.5	1
47	Cognitive Enhancement Down-Under. , 2016, , 147-158.		1
48	The Hidden Curriculum in Ethics and its Relationship to Professional Identity Formation: A Qualitative Study of Two Canadian Psychiatry Residency Programs. Canadian Journal of Bioethics, 0, 3, 80-92.	0.0	1
49	Ethical, Social and Clinical Challenges in using Deep Brain Stimulation to Treat Addiction and Other Impulsive and Compulsive Disorders. Jahrbuch FÃ¼r Wissenschaft Und Ethik, 2015, 19, 163-188.	0.3	0
50	Patient Preferences May Be Indicative ofÂNormative Issues in Dementia Research. Journal of Alzheimer's Disease, 2017, 59, 11-12.	1.2	0